Pyxis Oncology (PYXS) Equity Average (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Equity Average data on file, last reported at $61.1 million in Q4 2025.

• Equity Average for Q4 2025 came in at $61.1 million, down 55.48% year-over-year; the trailing twelve-month figure through Dec 2025 was $61.1 million (down 55.48% YoY), and the FY2025 annual result was $87.1 million, down 29.33% from the prior year.
• Equity Average fell to $61.1 million in Q4 2025 per PYXS's latest filing, from $78.2 million in the prior quarter.
• Over five years, Equity Average peaked at $247.4 million in Q1 2022 and troughed at -$64.5 million in Q3 2021.
• A 5-year average of $117.3 million and a median of $139.4 million in 2023 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2025: Equity Average jumped 853.6% in 2022, then plunged 55.48% in 2025.
• A 5-year view of Equity Average shows it stood at $94.9 million in 2021, then soared by 84.11% to $174.8 million in 2022, then fell by 24.58% to $131.8 million in 2023, then gained by 4.09% to $137.2 million in 2024, then tumbled by 55.48% to $61.1 million in 2025.
• Business Quant data shows PYXS's Equity Average at $61.1 million in Q4 2025, $78.2 million in Q3 2025, and $95.4 million in Q2 2025.